The Blackstone Group, a major US private equity firm, has announced the acquisition of Takeda Consumer Healthcare Company (TCHC), a subsidiary of Takeda Pharmaceutical. Investment funds and other industries have been putting out feelers toward the pharmaceutical sector in recent…
HOME > REGULATORY
REGULATORY
- Bid-Rigging Scandal by Wholesalers “Interferes with” Development of Pharma Industry: MHLW Bureau Chief
September 9, 2020
- Japan to Earmark 671.4 Billion Yen to Secure Coronavirus Vaccines, Anticipating Final Agreements with 3 Companies
September 9, 2020
- 1st COVID-19 Case Confirmed at NIHS
September 9, 2020
- Coronavirus Vaccines “Will Need to Be Evaluated More Carefully than Ordinary Medicines”: Top MD Bureaucrat
September 8, 2020
- Sakigake Status Should Not Be Granted to Novartis Products until It Takes Prevention Measures for Approval Delay: Pharma Bureau Chief
September 8, 2020
- Rakuten Medical’s Sakigake-Designated Photoimmunotherapy Clears MHLW Panel
September 8, 2020
- Medical Professionals to Be Prioritized in COVID-19 Vaccination: Govt Panel
September 8, 2020
- PMDA Reviewing Safety Risks for Takecab, 2 Other Drugs
September 7, 2020
- Former Pharma Bureau Chief Tarumi to Assume Vice Health Minister on September 14
September 7, 2020
- PMDA Presents Views on Efficacy, Safety Evaluations for Domestic Development of COVID-19 Vaccines
September 4, 2020
- Govt Holds 1st Meeting of Regenerative Medicine/Cell Therapy Panel, Eyeing Proposals in FY2021
September 4, 2020
- Will Temporary Measures in R&D Tax Credit System Be Extended? Enthusiasm for R&D Investment Could Determine Outcome
September 3, 2020
- MHLW Names 9 Candidates for Independent Safety Monitoring Panel for Pharma Products
September 3, 2020
- AMED Confirms 1st COVID-19 Case at HQ
September 3, 2020
- Japan Weighs COVAX Participation with Optional Purchase Arrangement
September 2, 2020
- AMED to Fund 7 More Company-Led COVID-19 Vaccine Projects Including Takeda, Daiichi Sankyo
September 2, 2020
- Japan Rolls Out Full-Fledged Sakigake System, Designations 2 Times a Year with Tougher Revocation Rules
September 1, 2020
- AMED to Focus on 5 Initiatives Including Strengthening Cooperation with Govt: New Chief
September 1, 2020
- Healthcare Spend Reaches Record 43.6 Trillion Yen in FY2019: MHLW
September 1, 2020
- MHLW Panel Roughly OKs Report on Stable API Supply Measures
August 31, 2020
ページ
Measures focusing on risk management should be necessary to prevent disruptions in API supplies, Prof. Hiroyuki Sakamaki of Kanagawa University…
Nearly a year after the introduction of the Ministry of Health, Labor and Welfare’s (MHLW) drug promotion guidelines in April…
Advancements in modified oligonucleotide technologies has been the key driver behind a spate of approvals in the oligonucleotide therapeutics space…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
A total of 51 new drugs joined the NHI price list in 2019, which are expected to generate combined peak sales of 373 billion yen, according to Jiho’s tally of data submitted to a key reimbursement policy panel. The relatively…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
Japan’s pharmaceutical industry has been in dire need of a shake-up, and as we continue to grapple with the COVID-19 pandemic, one thing is remarkably clear. It’s no longer business as usual, and we’re enjoying a front-row seat to some…